Study protocol for a telephone-based smoking cessation randomized controlled trial in the lung cancer screening setting: The lung screening, tobacco, and health trial

Kathryn L. Taylor, Danielle E. Deros, Shelby Fallon, Jennifer Stephens, Emily Kim, Tania Lobo, Kimberly M. Davis, George Luta, Jinani Jayasekera, Rafael Meza, Cassandra A. Stanton, Raymond Niaura, David Abrams, Brady McKee, Judith Howell, Michael Ramsaier, Juan Batlle, Ellen Dornelas, Vicky Parikh, Eric Anderson

Research output: Contribution to journalArticle


Lung cancer mortality can be reduced by 20% via low dose CT lung cancer screening (LCS) and treatment of early-stage disease. Providing tobacco use treatment to high risk cigarette smokers in the LCS setting may result in health benefits beyond the impact of LCS. As one of the nine trials in the National Cancer Institute's Smoking Cessation at Lung Examination (SCALE) collaboration, the goal of the Lung Screening, Tobacco, and Health (LSTH) trial is to develop a scalable and cost-effective cessation intervention for subsequent implementation by LCS programs. Guided by the RE-AIM Framework, the LSTH trial is a two-arm RCT (N = 1330) enrolling English- and Spanish-speaking smokers registered for LCS at one of seven collaborating sites. Participants are randomly assigned to Usual Care (UC; three proactive telephone counseling sessions/two weeks of nicotine patches) vs. Intensive Telephone Counseling (ITC; eight proactive sessions/eight weeks of nicotine patches, plus discussion of the LCS results to increase motivation to quit). Telephone counseling is provided by tobacco treatment specialists. To increase continuity of care, referring physicians are notified of participant enrollment and smoking status following the intervention. Outcomes include: 1) self-reported 7-day, 30-day, and sustained abstinence, and biochemically-verified at 3-, 6-, and 12-months post-randomization, 2) reach and engagement of the interventions, and 3) cost-effectiveness of the interventions. The Cancer Intervention and Surveillance Modeling Network (CISNET) will model long-term impacts of six SCALE trials on the cost per life year saved, quality-adjusted life years saved, lung cancer mortality reduction, and population mortality. Clinical trials registration: The trial is registered at clinical NCT03200236.

Original languageEnglish (US)
Pages (from-to)25-35
Number of pages11
JournalContemporary Clinical Trials
Publication statusPublished - Jul 1 2019


ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this